This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.

Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.

Source: Science Source Images The IFM2017-03 trial, which showed positive results with a dexamethasone-sparing regimen, is “one of the most practice-changing” studies presented at ASH 2024 ...

Disease-free and overall survival outcomes were similar across dosing schedules. Patients with high-risk early breast cancer have similar survival outcomes with different dosing schedules of ...

(HealthDay News) — The risk of melanoma-related death is greater for patients with primary tumors that are 0.8-1.0 mm thick than for patients with thinner tumors, according to a study published ...